CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 4 enrolled
Drug / intervention
Infinitomeprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04563767
NCT04563767N/ACompleted

Feasibility of Utilizing the Infinitome Program to Evaluate Abnormal Large Scale Brain Networks in Alzheimer's Disease

HealthPartners Institute·observational·Posted Sep 24, 2020·Updated Feb 17, 2021

In Brief

An observational study evaluating Infinitome for Alzheimer Disease. Completed, enrolled 4 participants across 1 site.

Detailed Summary

The Infinitome Program from Omniscient has the ability to identify abnormal brain networks or connectomes using resting state functional MRI (rs-fMRI). This technology, which visualizes brain networks in three dimensions, was originally developed to ensure neurosurgeons avoid inadvertently lesioning cognitively eloquent brain regions during surgical operations. The potential of Infinitome in identifying connectome dysfunction for neurodegenerative diseases such as Alzheimer's disease has yet to be explored. This diagnostic technique may play a critical role for identifying disease brain networks that may benefit from targeted interventions in clinical trials.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedSep 24, 2020
Enrollment StartSep 15, 2020
Primary CompletionOct 13, 2020
TodayJul 2, 2026
Enrollment to primary: 28 daysPosted 5.8 years ago

Interventions

Infinitomeprocedure

Added sequence of rs-fMRI.